Effects of lergotrile on schizophrenia & drug induced parkinsonism.
D000097:Acetonitriles / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D000328:Adult; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D011388:Prolactin / Q000037:antagonists & inhibitors*; D012559:Schizophrenia / Q000188:drug therapy*
D000097:Acetonitriles; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D004873:Ergolines; D011388:Prolactin; D005476:Fluphenazine